ACCESS-1NCT05133531
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 30 versions: 30 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 13 words Show 5 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Oct 12, 2026 to Sep 28, 2026
- Study completion date changed from estimate of Oct 26, 2026 to Oct 29, 2026
- Secondary endpoints: details revised at 4 of 28 entries
- Site details revised at 9 of 68 sites
Minor Trial status changed: Recruiting → Active, Not Recruitingv29 Show 4 more changesShow less
- Primary completion moved earlier from Jan 28, 2027 to Oct 12, 2026
- Study completion moved earlier from Jan 28, 2027 to Oct 26, 2026
- Enrollment target: estimated 190 to confirmed 202
- Study sites: 69 to 68
- Minor Study sites revised (69)v28
- Minor Site contacts updated at 1 of 69 sitesv27
- Minor Study sites: 65 to 69v26
Show 24 earlier versionsHide 24 earlier versions
- Minor Site details revised at 4 of 65 sitesv25
- Minor Study sites: 63 to 65v24
- Minor Site details revised at 1 of 63 sitesv23
- Minor Site details revised at 2 of 63 sitesv22
Notable Eligibility criteria expanded, about 21 wordsv21 Show 4 more changesShow less
- Primary endpoints revised (3)
- Primary and study completion dates: Apr 1, 2027 to Jan 28, 2027
- Secondary endpoints: details revised at 3 of 28 entries
- Site details revised at 5 of 63 sites
- Minor Site details revised at 7 of 63 sitesv20
- Minor Study sites: 62 to 63v19
- Minor Study sites: 61 to 62v18
- Minor Study sites: 60 to 61v17
- Minor Site details revised at 1 of 60 sitesv16
- Minor Study sites: 58 to 60v15
- Minor Study sites: 55 to 58v14
- Study Status, Referencesv13
- Minor Study sites: 51 to 55v12
- Minor Study sites: 48 to 51v11
- Notable Eligibility criteria shortened, about 2 words
- Primary and study completion dates: Mar 29, 2027 to Apr 1, 2027
- Secondary endpoints: details revised at 2 of 28 entries
- Notable Eligibility criteria expanded, about 39 words
- Primary and study completion dates: Mar 1, 2027 to Mar 29, 2027
- Study title revised
- Minor Study sites revised (48)v8
- Notable Eligibility criteria expanded, about 2 words
- Study sites: 45 to 48
Notable Primary completion date: Mar 2, 2026 to Mar 1, 2027v6 Show 7 more changesShow less
- Eligibility criteria expanded, about 14 words
- Primary endpoints: 2 to 3
- Enrollment target: 148 to 190
- Study sites: 36 to 45
- Interventions: Cemdisiran (Drug), Pozelimab (Drug), Ravulizumab (Drug) to Cemdisiran (Drug), Eculizumab (Drug), Pozelimab (Drug), Ravulizumab (Drug)
- Secondary endpoints: 25 to 28
- Study title expanded, about 2 words
- Minor Study sites: 9 to 36v5
Notable Eligibility criteria shortened, about 6 wordsv4 Show 8 more changesShow less
- Primary endpoints revised (2)
- Enrollment target: 124 to 148
- Study sites: 1 to 9
- Primary completion date: May 18, 2026 to Mar 2, 2026
- Study completion date: Jul 16, 2027 to Mar 1, 2027
- Start date changed from estimate of Jul 31, 2022 to Aug 1, 2022
- Secondary endpoints: 24 to 25
- Study title expanded, about 1 word
- Minor Study site revisedv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percent change in lactate dehydrogenase (LDH)
Timeframe: From baseline to week 26
Transfusion avoidance
Timeframe: From post-baseline day 1 through week 26
Adequate control of hemolysis
Timeframe: From week 8 through week 26, inclusive
Secondary (28)
Maintenance of adequate control of hemolysis
Breakthrough hemolysis
Adequate control of hemolysis
Hemoglobin stabilization
Normalization of LDH
Show 23 moreShow less
Transfusion avoidance
Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
Change in physical function (PF) scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
Change in global health status (GHS)/QoL scale score on the EORTC-QLC-C30
Percent change in LDH
Rate of RBC transfused
Number of units of RBC transfused
Time to first LDH ≤1.5 × ULN
Time to first LDH ≤1.0 × ULN
Percentage of days with LDH ≤1.5 × ULN
Change in hemoglobin levels
Incidence and severity of treatment emergent serious adverse events (SAEs)
Incidence and severity of treatment-emergent adverse events (TEAEs) of special interest
Incidence and severity of TEAEs leading to treatment discontinuation
Change in total CH50
Percent change in total CH50
Concentration of total C5 in plasma
Concentrations of total pozelimab in serum
Concentrations of cemdisiran in plasma
Concentrations of total ravulizumab in serum
Concentrations of total eculizumab in serum
Incidence of treatment emergent anti-drug antibodies (ADAs) to pozelimab
Incidence of treatment emergent ADAs to cemdisiran
Arms and interventions
Cohort AExperimental
Randomized 1:1
Cohort BExperimental
Randomized 1:1
Drugs: Ravulizumab, Pozelimab, Cemdisiran, Eculizumab
Sites
68 sites in 24 countries
South Korea 9, Taiwan 9, India 8, Japan 5, Spain 4, Thailand 4, Brazil 3, Italy 3, Malaysia 3, Poland 3, Romania 3, Turkey (Türkiye) 2, Canada 1, China 1, Colombia 1, Greece 1, Hungary 1, Jordan 1, Mexico 1, Peru 1, Philippines 1, Singapore 1, United Kingdom 1, United States 1